clinical trial · NCT07059767
Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge
Asthma (Diagnosis)ETH47Placebo
brief summary
A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge
started
Jun 24, 2025
primary completion
Jun 1, 2026
completion
Jun 1, 2026
last updated
Aug 11, 2025
official title
A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol